A5074069242- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Drug-Induced Hepatotoxicity and Protection
- Pathogenesis and Treatment of Hiccups
- Health Systems, Economic Evaluations, Quality of Life
- Complementary and Alternative Medicine Studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
Johnson & Johnson (United States)
2024-2025
Janssen (United States)
2022-2024
Janssen Scientific Affairs (United States)
2022-2023
Ridgeview
2023
Chapel Allerton Hospital
2023
Abstract Background Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin (IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but not shown efficacy treating ankylosing spondylitis (AS), suggesting differences axPsA processes and treatments. In post hoc, pooled analysis patients with investigator- imaging-confirmed sacroiliitis two phase 3, randomized, placebo-controlled studies (DISCOVER-1 DISCOVER-2), treated guselkumab, an...
Introduction Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with skin psoriasis that, if left untreated, can lead to joint destruction. Up 30% of patients progress PsA. In most cases, precedes synovio-entheseal inflammation by an average 5–7 years, providing unique opportunity for early and potentially preventive intervention in susceptible identifiable population. Guselkumab effective IL-23p19 inhibitor Food Drug Administration (FDA)-approved treatment...
Psoriatic arthritis (PsA) is a multi-domain, inflammatory disease impacting joints, soft tissues, and skin; tumor necrosis factor inhibitors (TNFi) are typically the first biologic following inadequate response (IR) to conventional therapies. Although guidance lacking on therapy selection after initial TNFi failure, data suggest TNFi-IR PsA patients may benefit from switching different mechanism of action (MOA) vs. cycling another TNFi. Guselkumab fully human monoclonal antibody targeting...
Abstract Objective In the absence of axial psoriatic arthritis (axPsA)-specific tools, BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) are used to assess symptoms in patients with PsA. Here, we assessed performance ASDAS Methods Patients active PsA DISCOVER-1 DISCOVER-2 (ClinicalTrials.gov: NCT03162796 NCT03158285, respectively) or without axPsA but available baseline information were analysed; those investigator-identified imaging-confirmed sacroiliitis comprised cohort....
This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late (LD).
We studied the effect of intravenous (IV)-golimumab on fatigue and association improvement with clinical response post hoc in adults active ankylosing spondylitis (AS) GO-ALIVE trial. Patients were randomized to IV-golimumab 2 mg/kg (N = 105) at week (W) 0, W4, then every 8 W (Q8W) or placebo 103) W0, W12, crossover W16, W20, Q8W through W52. Fatigue measures included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question #1 (fatigue; 0 [none], 10 [worst]; decrease indicates...
<h3>Background</h3> Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess activity of axial disease in patients (pts) with psoriatic arthritis (PsA), only one its questions specific symptoms. Alternatively, Score (ASDAS) excludes assessment enthesitis, gives less weight peripheral and considered more objective than BASDAI. <h3>Objectives</h3> The current post hoc analysis aimed compare performance BASDAI ASDAS evaluating symptoms involvement pts PsA...
<h3>Background</h3> Aside from the Tight Control in PsA (TICOPA) study, treatment strategy trials psoriatic arthritis (PsA), and definitive guidance on managing patients (pts) with inadequate response (IR) to a first tumor necrosis factor inhibitor (TNFi), are lacking. Recent observational studies suggest potentially greater benefit switching TNFi-IR pts new mechanism of action (MOA).<sup>[1]</sup> <h3>Objectives</h3> Design pragmatic trial (EVOLUTION) determine whether MOA, specifically...
Background Established criteria for classifying axial psoriatic arthritis (PsA) are lacking, and assessments of disease activity often rely on measures developed ankylosing spondylitis (AS). There is an unmet need to systematically identify measure efficacy treatments PsA patients (pts). Guselkumab (GUS), a selective interleukin (IL)-23p19 inhibitor, was efficacious in improving signs symptoms active 2 phase 3, randomized, placebo (PBO)-controlled studies: DISCOVER-1 DISCOVER-2. In post-hoc...